1. Home
  2. MXCT vs FMAC Comparison

MXCT vs FMAC Comparison

Compare MXCT & FMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

HOLD

Current Price

$1.11

Market Cap

136.0M

Sector

Health Care

ML Signal

HOLD

FMAC

Future Money Acquisition Corporation Ordinary Shares

N/A

Current Price

$10.01

Market Cap

157.5M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
MXCT
FMAC
Founded
1999
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
136.0M
157.5M
IPO Year
2021
2026

Fundamental Metrics

Financial Performance
Metric
MXCT
FMAC
Price
$1.11
$10.01
Analyst Decision
Buy
Analyst Count
4
0
Target Price
$5.50
N/A
AVG Volume (30 Days)
1.7M
7.6K
Earning Date
05-12-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$33,026,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$18.50
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.64
$9.95
52 Week High
$2.31
$10.02

Technical Indicators

Market Signals
Indicator
MXCT
FMAC
Relative Strength Index (RSI) 38.61 53.44
Support Level $1.08 $9.95
Resistance Level $1.16 N/A
Average True Range (ATR) 0.09 0.01
MACD -0.03 0.00
Stochastic Oscillator 6.10 85.71

Price Performance

Historical Comparison
MXCT
FMAC

About MXCT MaxCyte Inc.

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

About FMAC Future Money Acquisition Corporation Ordinary Shares

Future Money Acquisition Corp is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.

Share on Social Networks: